Given that CD44/STAT3 axis is involved in cancer progression and therapy resistance, we hypothesize that combinatorial administration of the most promising targeting agents, such as A6 blocking peptide against CD44 and Napabucasin against STAT3, can be beneficial for ovarian cancer patients in advanced disease stage and deserves further investigation. The gene discussed is CD44; the disease is ovarian cancer.